NCT06105619View on ClinicalTrials.gov

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 8, 2018

Primary Completion Date

April 1, 2023

Study Completion Date

December 31, 2024

Conditions

Glioblastoma

Interventions

DRUG

PLB1001

PLB1001 is a capsule in the form of 300mg,twice daily.

DRUG

Temozolomide

100-150mg/m2/d,day 1 to 7 and day 15 to 22 of each 28-day cycle

DRUG

Cisplatin combined with Etoposide

Cisplatin:80-100mg/m2/3 days,28 days/cycle Etoposide:100mg/m2/d,3 days,28 days/cycle

Trial Locations (1)

100070

Beijing Tiantan Hospital,Capital Medical University, Beijing

All Listed Sponsors

lead

Beijing Pearl Biotechnology Limited Liability Company

INDUSTRY

NCT06105619 - A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | Biotech Hunter | Biotech Hunter